Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sage Therapeutics, Inc. (NASDAQ: SAGE).

Full DD Report for SAGE

You must become a subscriber to view this report.


Recent News from (NASDAQ: SAGE)

Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 30, 2018 / U.S. markets closed lower on Thursday as investors await details from this weekend's trade meeting between President Trump and Chinese President Xi Jinping. The Dow Jones Industrial Average fell 0.11 percent to close at 25,338.84, while the S&a...
Source: ACCESSWIRE IA
Date: November, 30 2018 07:55
Sage Therapeutics receives PDUFA extension for ZULRESSO injection
Sage Therapeutics (NASDAQ: SAGE ) announces that the FDA has extended the PDUFA goal date from December 19, 2018 toMarch 19, 2019 for its Priority Review of the NDA for ZULRESSO (brexanolone) injection for the treatment of postpartum depression (PPD). More news on: Sage Therapeutics, Hea...
Source: SeekingAlpha
Date: November, 20 2018 08:34
Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO(TM) (brexanolone) Injection
PDUFA goal date extended to March 19, 2019 to finalize REMS No additional clinical data or information requested by the FDA Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system ...
Source: Business Wire
Date: November, 20 2018 07:30
Sage Therapeutics to Present at Stifel 2018 Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018...
Source: Business Wire
Date: November, 07 2018 16:01
Sage Therapeutics (SAGE) CEO Jeff Jonas on Q3 2018 Results - Earnings Call Transcript
Sage Therapeutics (SAGE) Q3 2018 Earnings Conference Call November 6, 2018 8:00 AM ET Executives Paul Cox - Head of Investor Relations Jeff Jonas - Chief Executive Officer Mike Cloonan - Chief Business Officer Kimi Iguchi - Chief Financial Officer Jim Doherty - Chief Research...
Source: SeekingAlpha
Date: November, 06 2018 21:02
Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
FDA Advisory Committee Meeting outcome supports approval of ZULRESSO™ (brexanolone) injection as the first medicine specifically indicated for the treatment of postpartum depression (PPD) Continuing to execute commercial strategy for ZULRESSO in PPD ahead of PDUFA target date ...
Source: Business Wire
Date: November, 06 2018 06:30
Notable earnings before Tuesday's open
AAC , ABC , ADM , AES , AFI , ANIP , APD , AVNS , BCC , BCPC , BDX , BHC , BIOS , BLD , BR , CORE , CTLT , CVS , ELAN , EMES , EMR , ETM , EXPD , FI , FRTA , FSS , GCP , GLDD , GLT , GOGO , GTN , GTX , HAE , HPT , HSIC , IONS , IRWD , JELD , JLL , KEYW...
Source: SeekingAlpha
Date: November, 05 2018 17:30
Positive Ad Com vote on Sage's brexanolone in PPD a positive for Marinus Pharma
Friday's thumbs up from an FDA advisory committee on Sage Therapeutics' (NASDAQ: SAGE ) GABA modulator brexanolone for postpartum depression (PPD) could stoke buying in Marinus Pharmaceuticals (NASDAQ: MRNS ). It is also developing a GABA modulator, ganaxolone, for PPD, albeit with a longer ...
Source: SeekingAlpha
Date: November, 05 2018 09:28
Denali Follows Up First-Mover Advantage In LRRK2 With Sanofi Deal To Evaluate RIPK1 Inhibitors
Understanding Denali as an investment I previously explored the over-arching potential of the unique 'transport vehicle' platform perfected by Denali Therapeutics ( DNLI ) for the shuttling of large-molecule therapeutics across the blood-brain-barrier. Since I posted that analysis, the ...
Source: SeekingAlpha
Date: November, 05 2018 08:56
Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval...
Source: ACCESSWIRE IA
Date: November, 05 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-08162.44160.94165.1572159.211157,284
2018-05-17175.01165.56175.09165.15580,998
2017-09-0785.8486.5987.4985.00291,958
2017-09-0685.9485.9886.67583.21284,391
2017-09-0586.8185.1687.600484.565289,315

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1056,746101,96855.6508Short
2018-12-0724,76438,86063.7262Short
2018-12-0630,46754,08356.3338Short
2018-12-0457,80494,52061.1553Short
2018-12-0339,62273,94253.5852Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SAGE.


About Sage Therapeutics, Inc. (NASDAQ: SAGE)

Logo for Sage Therapeutics, Inc. (NASDAQ: SAGE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $7,936,535,692 - 05/11/2018
  • Issue and Outstanding: 46,515,858 - 04/26/2018

 


Recent Filings from (NASDAQ: SAGE)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: SAGE)

Daily Technical Chart for (NASDAQ: SAGE)


Stay tuned for daily updates and more on (NASDAQ: SAGE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SAGE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SAGE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SAGE and does not buy, sell, or trade any shares of SAGE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/